{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:43:06Z","timestamp":1792204986303,"version":"4.4.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ejca.2022.03.032","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T05:59:31Z","timestamp":1651211971000},"page":"32-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma"],"prefix":"10.1016","volume":"169","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0772-1604","authenticated-orcid":false,"given":"Christina","family":"Pamporaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Prodanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Meuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika M.A.","family":"Berends","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6932-333X","authenticated-orcid":false,"given":"Nicole","family":"Bechmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgiana","family":"Constantinescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Beuschlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Remde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Januszewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel N.","family":"Kerstens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1208-5748","authenticated-orcid":false,"given":"Henri J.L.M.","family":"Timmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ta\u00efeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6256-5902","authenticated-orcid":false,"given":"Mercedes","family":"Robledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7658-4466","authenticated-orcid":false,"given":"Jacques W.M.","family":"Lenders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Pacak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8601-9903","authenticated-orcid":false,"given":"Graeme","family":"Eisenhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ejca.2022.03.032_bib1","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.5858\/2008-132-1272-PAEPU","article-title":"Pheochromocytoma and extra-adrenal paraganglioma: updates","volume":"132","author":"Tischler","year":"2008","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ejca.2022.03.032_bib2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.humpath.2020.04.012","article-title":"Data set for the reporting of pheochromocytoma and paraganglioma: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting","volume":"110","author":"Thompson","year":"2021","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.ejca.2022.03.032_bib3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"issue":"18","key":"10.1016\/j.ejca.2022.03.032_bib4","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.3390\/cancers13184602","article-title":"Insights into mechanisms of pheochromocytomas and paragangliomas driven by known or new genetic drivers","volume":"13","author":"Flores","year":"2021","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.ejca.2022.03.032_bib5","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","article-title":"Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status","volume":"48","author":"Eisenhofer","year":"2012","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2022.03.032_bib6","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1373\/clinchem.2018.291369","article-title":"Biochemical diagnosis of chromaffin cell tumors in patients at high and low risk of disease: plasma versus urinary free or deconjugated O-methylated catecholamine metabolites","volume":"64","author":"Eisenhofer","year":"2018","journal-title":"Clin Chem"},{"issue":"4","key":"10.1016\/j.ejca.2022.03.032_bib7","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1210\/jc.2004-2025","article-title":"Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine","volume":"90","author":"Eisenhofer","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"49","key":"10.1016\/j.ejca.2022.03.032_bib8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jncimonographs\/lgu024","article-title":"Cancer survival: an overview of measures, uses, and interpretation","author":"Mariotto","year":"2014","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"1","key":"10.1016\/j.ejca.2022.03.032_bib9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2796.2005.01504.x","article-title":"Long-term outcome of a large series of patients surgically treated for pheochromocytoma","volume":"258","author":"Khorram-Manesh","year":"2005","journal-title":"J Intern Med"},{"key":"10.1016\/j.ejca.2022.03.032_bib10","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1186\/1471-2407-14-523","article-title":"The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study","volume":"14","author":"Schovanek","year":"2014","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2022.03.032_bib11","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Ayala-Ramirez","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ejca.2022.03.032_bib12","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1677\/ERC-08-0049","article-title":"Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma","volume":"15","author":"Timmers","year":"2008","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2022.03.032_bib13","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11912-013-0320-x","article-title":"Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma","volume":"15","author":"Jimenez","year":"2013","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"10.1016\/j.ejca.2022.03.032_bib14","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/jso.23297","article-title":"Malignant pheochromocytoma and paraganglioma: a population level analysis of long-term survival over two decades","volume":"107","author":"Goffredo","year":"2013","journal-title":"J Surg Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2022.03.032_bib15","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1210\/jc.2007-0709","article-title":"Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas","volume":"92","author":"Amar","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ejca.2022.03.032_bib16","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.amjoto.2013.03.010","article-title":"Malignant head and neck paragangliomas: treatment efficacy and prognostic indicators","volume":"34","author":"Sethi","year":"2013","journal-title":"Am J Otolaryngol"},{"key":"10.1016\/j.ejca.2022.03.032_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1758-3284-2-23","article-title":"Malignant head and neck paragangliomas: is there an optimal treatment strategy?","volume":"2","author":"Moskovic","year":"2010","journal-title":"Head Neck Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2022.03.032_bib18","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/cncr.10252","article-title":"American college of surgeons commission on cancer; American cancer society national cancer data base report on malignant paragangliomas of the head and neck","volume":"94","author":"Lee","year":"2002","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2022.03.032_bib19","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4158\/EP15725.OR","article-title":"Characteristics and outcomes of metastatic SDHB and sporadic pheochromocytoma\/paraganglioma: an national Institutes of Health study","volume":"22","author":"Turkova","year":"2016","journal-title":"Endocr Pract"},{"issue":"9","key":"10.1016\/j.ejca.2022.03.032_bib20","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1210\/jc.2017-00992","article-title":"Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years","volume":"102","author":"Hamidi","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ejca.2022.03.032_bib21","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/jc.2018-01968","article-title":"Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono study): a European network for the study of adrenal tumors retrospective study","volume":"104","author":"Hescot","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ejca.2022.03.032_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1530\/EJE-17-0077","article-title":"Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma","volume":"177","author":"Rao","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"6937","key":"10.1016\/j.ejca.2022.03.032_bib23","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0140-6736(56)92083-9","article-title":"Identification of hydroxytyramine in a chromaffin tumour","volume":"271","author":"Mcmillan","year":"1956","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejca.2022.03.032_bib24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1530\/eje.0.1470085","article-title":"The value of plasma markers for the clinical behaviour of phaeochromocytomas","volume":"147","author":"van der Harst","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.ejca.2022.03.032_bib25","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1365-2125.1981.tb01210.x","article-title":"Renal conversion of plasma DOPA to urine dopamine","volume":"12","author":"Brown","year":"1981","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.ejca.2022.03.032_bib26","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1042\/cs0840549","article-title":"Derivation of urinary dopamine from plasma dihydroxyphenylalanine in humans","volume":"84","author":"Wolfovitz","year":"1993","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"10.1016\/j.ejca.2022.03.032_bib27","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0022-3565(25)31537-5","article-title":"Tubular secretion and metabolism of dopamine, norepinephrine, methoxytyramine and normetanephrine by the rat kidney","volume":"208","author":"Baines","year":"1979","journal-title":"J Pharmacol Exp Therapeut"},{"issue":"15","key":"10.1016\/j.ejca.2022.03.032_bib28","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.clinbiochem.2016.05.008","article-title":"Low specificity of urinary 3-methoxytyramine in screening of dopamine-secreting pheochromocytomas and paragangliomas","volume":"49","author":"Patin","year":"2016","journal-title":"Clin Biochem"},{"issue":"9","key":"10.1016\/j.ejca.2022.03.032_bib29","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1002\/ijc.28868","article-title":"Opposing effects of HIF1\u03b1 and HIF2\u03b1 on chromaffin cell phenotypic features and tumor cell proliferation: insights from MYC-associated factor X","volume":"135","author":"Qin","year":"2014","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2022.03.032_bib30","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0002-9440(10)64400-8","article-title":"Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors","volume":"161","author":"Favier","year":"2002","journal-title":"Am J Pathol"},{"issue":"11","key":"10.1016\/j.ejca.2022.03.032_bib31","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1530\/ERC-20-0205","article-title":"HIF2\u03b1 supports pro-metastatic behavior in pheochromocytomas\/paragangliomas","volume":"27","author":"Bechmann","year":"2020","journal-title":"Endocr Relat Cancer"},{"issue":"7618","key":"10.1016\/j.ejca.2022.03.032_bib32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nature19081","article-title":"Tumour hypoxia causes DNA hypermethylation by reducing TET activity","volume":"537","author":"Thienpont","year":"2016","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.ejca.2022.03.032_bib33","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1016\/j.celrep.2020.03.022","article-title":"TET-mediated hypermethylation primes SDH-deficient cells for HIF2\u03b1-driven mesenchymal transition","volume":"30","author":"Morin","year":"2020","journal-title":"Cell Rep"},{"issue":"6","key":"10.1016\/j.ejca.2022.03.032_bib34","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ccr.2013.04.018","article-title":"SDH mutations establish a hypermethylator phenotype in paraganglioma","volume":"23","author":"Letouz\u00e9","year":"2013","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.ejca.2022.03.032_bib35","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/path.4900","article-title":"Cousins not twins: intratumoural and intertumoural heterogeneity in syndromic neuroendocrine tumours","volume":"242","author":"Flynn","year":"2017","journal-title":"J Pathol"},{"issue":"1","key":"10.1016\/j.ejca.2022.03.032_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ERC-17-0306","article-title":"TERT structural rearrangements in metastatic pheochromocytomas","volume":"25","author":"Dwight","year":"2018","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2022.03.032_bib37","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/MPA.0000000000001792","article-title":"The north American neuroendocrine tumor society consensus guidelines for surveillance and management of metastatic and\/or unresectable pheochromocytoma and paraganglioma","volume":"50","author":"Fishbein","year":"2021","journal-title":"Pancreas"},{"issue":"3","key":"10.1016\/j.ejca.2022.03.032_bib38","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1530\/EJE-14-0113","article-title":"Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma","volume":"171","author":"Baudin","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"10.1016\/j.ejca.2022.03.032_bib39","doi-asserted-by":"crossref","first-page":"T41","DOI":"10.1530\/ERC-19-0435","article-title":"Hereditary endocrine tumours: current state-of-the-art and research opportunities: metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshop","volume":"27","author":"Dahia","year":"2020","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2022.03.032_bib40","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3390\/cancers11101505","article-title":"Current management of pheochromocytoma\/paraganglioma: a guide for the practicing clinician in the era of precision medicine","volume":"11","author":"N\u00f6lting","year":"2019","journal-title":"Cancers"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922001800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922001800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:35:24Z","timestamp":1760733324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922001800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":40,"alternative-id":["S0959804922001800"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.03.032","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.03.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}